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Fentanyl, with an analgesic potency of about 80 times that of morphine, was intro-
duced into medical practice in the early 1970s for parenteral use in anesthesia. In 1991,
transdermal reservoir patches (RPs) of fentanyl were approved for the treatment of chro-
nic and cancer pains (1). Delivering of drugs into systemic circulation through skin has
attracted a great deal of interest during the last couple of decades (2). Transport of com-
pounds via skin is considered to be a complex phenomenon, which allows the passage
of certain chemicals into and across the skin (3). The understanding of this complex phe-
nomenon has lead to the development of transdermal drug delivery systems (TDDSs),
in which skin serves as the site for administration of systemically active compounds
such as fentanyl (4).
Among the various skin layers, stratum corneum (SC) is the rate-limiting barrier to
percutaneous drug transport due to its desquamating 'horny' properties, comprising about
15–20 rows of flat, partially desiccated, dead, keratinized epidermal cells (5). Due to the
lipid-rich nature of the SC layer (40% lipids, 40% protein, and only 20% water) and its
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low water content, transport of hydrophilic or charged molecules across SC is low while
transport of lipophilic drug molecules such as fentanyl is higher due to their lipid misci-
bility with intercellular lipids around the cells in the SC layer (6).
Preparation of TDDSs consists of three basic designs: membrane control or RPs, ma-
trix or monolithic patches (MPs), and DIAPs (see Scheme 1). Several factors should be
considered before choosing an appropriate design for a particular compound: drug solu-
bility, stability and release rate. As a rule of thumb, if a drug permeates or crosses the
skin faster than desired, RPs can slow down or control the permeation (7). Alternatively,
if a drug passes through skin at a slower rate than the patch releases it, MPs probably
containing a suitable chemical penetration enhancer may suffice. These systems consist
of a backing layer, a polymeric matrix, an adhesive and a protective liner (7, 8).
In the early days of TDDS development, the worldwide mainstream was represen-
ted by the complicated structure of the reservoir type, in which the presence of a rate-
controlling membrane was considered essential in order to achieve the drug release con-
trol. The very antithesis to the RPs are the so-called DIAPs, in which the overall function
is achieved by concentrating the required functions into a single component of the adhe-
sive polymer, which is definitely simple in structure (9). When the characteristics of the-
se three different patches are compared (Table I), DIAPs and MPs are clearly superior to
RPs in terms of patient compliance (7). It might also be expected, because of their simple
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Scheme 1
Table I. Characteristics of drug-in-adhesive and matrix patches vs. reservoir patches





















Italics indicate superior characteristics.
structure, that DIAPs and MPs are superior from the commercial viewpoint in terms of
the manufacturing process control, quality control and continuous product improvement.
Moreover, the thinner construction of MPs and DIAPs may improve wearing comfort for
the patient (10). However, drug formulations for MPs are more challenging to produce,
particularly for those patches that incorporate the drug in the adhesive (11). The purpo-
se of the present research work was to design new MPs and preferably DIAPs for fenta-
nyl by regulating their drug release and adhesive properties.
EXPERIMENTAL
Materials
Micronized fentanyl was obtained from Diosynth (The Netherlands). Hydroxyl ethyl
cellulose (HEC), ethyl cellulose (EC), and Carbomer 940 were from Clariant (Germany),
Aqualon (The Netherlands), and 3V Sigma (Italy), respectively. Hydroxypropyl methyl-
cellulose (HPMC K4M, HPMC K15M and HPMC K100M) and Eudragit® E were from
Colorcon (UK) and Rohm (Germany), respectively.
Reference fentanyl RP formulation was Duragesic® 25 and 50 g h–1 (10 and 20 cm2,
respectively) from Janssen-Cilag (Belgium).
Control membranes, CotranTM, were donated by 3M (USA). Control membranes
used in this study include: CotranTM 9702 membrane, 50 µm, 9% vinyl acetate (VA), Cot-
ranTM 9706 membrane, 100 µm, 9% VA, and CotranTM 9728 membrane, 50 µm, 19% VA.
These control membranes consist of ethylene vinyl acetate (EVA) containing 9% or 19%
VA. Control membranes with a higher amount of VA have more drug permeability and
also higher moisture vapor transmission rates (MVTR).
CotranTM backing layers were also donated by 3M. Backings used in this study in-
clude: CotranTM 9720 backing, 75 µm, polyethylene, CotranTM 9722 backing, 75 µm, po-
lyolefin, and ScothpacTM 9723 backing, 42 µm, polyester-based laminates polyethylene –
polyester. The backings have both a low MVTR and high oxygen transmission. These
foster improved skin health by increasing moisture close to the skin to maintain skin
hydration while allowing it to breathe.
The transferring PSA films, MA-31, MA-46, and HY-3 were gifts from Adhesive Re-
search (USA) and 3M-1524 transferring PSA, 62.5 µm from 3M. Acronal® V 210, a 70%
aqueous dispersion of carboxylated copolymer based on acrylate in combination with
vinyl acetate, was kindly donated by BASF (Germany). Release liner, also known as pee-
ling or protective liner, 3M ScotchpakTM 1022 liner, was donated by 3M.
Quadruple laboratory film applicator with a lateral guide plate and 4 thickness
choices – 90, 170, 250, 500 m, and a 90 mm gap width was purchased from Sandberg &
Schneidewind (Germany).
Support membrane (Spectra/Por® 7 with cut off 14000 Daltons) to fix patches in the
dissolution vessel was purchased from Spectrum (USA). All solvents and reagents used
were of analytical reagent grade and solutions were prepared with purified water (con-
ductivity less than 1 S cm–1).
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Preparation of fentanyl TDDS
Preparation of fentanyl RPs. – RPs consist of a backing layer, a drug reservoir, a rate-
-controlling membrane and an adhesive layer covered by a protective release liner. The
active compound within RPs may exist as either a liquid or a gel or dispersed in a poly-
meric material. Full factorial design was applied by using three different concentrations
of the gelling polymer (HEC 2, 3 and 4 percent), three types of the rate-controlling mem-
brane with different percentages of VA content and various thickness, and solution and
suspension formulations of fentanyl in its vehicle.
The rate-controlling membranes consisted of controlled caliper EVA microporous
membrane films, which were heat-sealable to polyethylene and polyester backings. Dif-
ferent backing layers were also tested to find the perfect sealing matching our sealing
device and its temperature. After sealing, the RPs were checked by the leak test in a va-
cuum desiccator.
The adhesive layer of the patches was hypoallergenic acrylate or silicone transfer-
ring film PSA. The composition of some polymeric mixtures used to prepare the RPs is
shown in Table II.
Backing layer and rate-controlling membrane were cut separately into circular pie-
ces having a 3.6 cm diameter corresponding to a 10 cm2 surface area. After applying an
appropriate amount of gel containing fentanyl, their rims were sealed at 150 °C for 4–8
seconds by a heat sealing device developed in our laboratory. After cutting, RPs were
protected using a protective release liner and finally each individual patch was packed
in an opaque, white heat-sealed pouch. The pouch had laminated construction of bleac-
hed machine-glazed paper, low density polyethylene, aluminum foil (9 m) and an in-
ner low-density polyethylene heat-seal layer.
Preparation of fentanyl MPs. – MPs were prepared using a quadruple laboratory film
applicator. Transdermal matrices of fentanyl were made using various concentrations of
HPMC (K4M, K15M and K100M), ethyl cellulose, HEC, and Eudragit® E.
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Table II. Composition of some typical polymeric mixtures used for the preparation of fentanyl RPs
Compound R Sus 1 R Sol 2 R Sus 5 R Sol 8 R Sus 10
Fentanyl 2.5 2.5 2.5 2.5 2.5
Alcohol 0.1 0.2 0.1 0.2 0.1
HECa 8 8 – 12 16
HPMC K15M – – 8 – –
Glycerol – – – – 0.1
Water 0.3 0.2 0.3 0.2 0.2
R, Sus, and Sol denote reservoir, suspension, and solution, respectively.
Amounts are expressed in mg (except for alcohol and purified water which are in mL).
a 8, 12, and 16 mg correspond to 2, 3, and 4% (m/V) polymer in the solvent, respectively.
The accurate amount of drug per 10 cm2 of patch was determined by varying the
matrix thickness and appropriate percentage of fentanyl loaded in the dried matrix. The
drug/polymer ratios used were between 1:10 and 1:20. Initially, according to the afore-
mentioned ratio, drug and polymer were dissolved separately in alcohol and water. The
two solutions were mixed and then glycerin or propylene glycol or another suitable plasti-
cizer was incorporated. The mixture was then poured into the film applicator and spread
on the backing layer at a constant rate of 1 m min–1 with a constant wet thickness of 90,
170, 250 or 500 m to obtain an acceptable amount of fentanyl per 10 cm2. The films
were dried in an oven at 60 °C for 15 min and then cut into a predetermined area contai-
ning an equivalent of 5 mg of fentanyl per each 10 cm2. PSA sheets were then transferred
onto the matrices and then the patches were protected using release liners, and finally
each individual patch was packed in an opaque, white heat-sealed pouch as explained
above. The composition of some polymeric mixtures used to prepare the MPs is shown
in Table III.
Preparation of DIAPs. – The DIAPs were made of a flexible backing, a self adhesive
controlled-release matrix containing fentanyl, and a release liner. The accurate amount
of drug per 10 cm2 of DIAP was determined by varying matrix thickness and appropria-
te percentage of fentanyl loaded in the dried DIAP. Aqueous methacrylic systems such
as Acronal® and also cross-linked Eudragit® E were chosen for the preparation of the
DIAPs. The latter is non-irritant and well tolerated by the skin and has two desired pro-
perties, release-rate controll and self adhesion after cross linking with succinic acid (12).
The adhesive matrix was prepared from an organic acid such as succinic acid and alco-
holic solution of Eudragit® E. The composition of some polymeric mixtures used to pre-
pare the DIAPs is shown in Table IV.
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Table III. Composition of some typical polymeric mixtures used for the preparation of fentanyl MPs
Compound M 1 M Sus 5 M Sol 8 M 9 M 15
Fentanyl 5 5 5 5 5
Alcohol 0.1 – 0.17 0.17 0.17
HEC 50 – – –
HPMC K15M – 50 – – –
Ethyl cellulose – – – – 60
Eudragit® E 100 – – 75 75
Glycerol – 2.5 3.75 – 6
Propylene glycol 5 2.5 – 15 –
Dibutyl sebacate – – 15 – 6
Water q. s. q. s. 0.19 0.19 0.19
M, Sus, and Sol denote matrix, suspension, and solution, respectively.
Amounts are expressed in mg, except for alcohol and purified water which are in mL.
q. s. – quantum satis
Macroscopic and microscopic examinations
In the case of suspension formulations, the presence of solid particles in the formu-
lations was evaluated using a 8  60 Binoculars microscope (Zeiss, Germany). Evidence
of any pin or defective sealing in RPs was evaluated by the leak test. This test was per-
formed with a vacuum desiccator filled with methylene blue solution. Due to the impor-
tance of thickness in MPs and DIAPs, the thickness of the film in different areas was eva-
luated by a caliper or thickness measuring device.
Determination of solubility and analysis of fentanyl
Excess amounts of fentanyl were added to two different media, purified water and
phosphate buffer solution (PBS), pH 7.2, and were agitated for 24 h at 23 ± 2 °C. The sus-
pensions were filtered through a membrane filter of 0.45 m to obtain a clear solution,
and the concentrations of fentanyl were measured by a validated HPLC method as fol-
lows. Fentanyl content was analyzed using HPLC-UV (series 486 Waters, USA) at a de-
tection wavelength of 230 nm. The column type was a reversed phase bondapack C18
(300  3.9 mm i.d., 10 m particle size, Waters) and maintained at 40 °C. The mobile pha-
se was 40:60 of ammonium acetate solution (1:100) and a mixture of methanol, acetonit-
rile, and glacial acetic acid (400:600:0.6). The pH of the mobile solution was adjusted to
6.6 ± 0.1 by dropwise addition of glacial acetic acid. The retention time and flow rate we-
re 4.2 minutes and 2 mL min–1, respectively (13).
In vitro release of fentanyl
Determination of the fentanyl release pattern in different RPs, MPs, and DIAPs and
their comparison with reference RPs were carried out using a USP 26 (14) apparatus 5,
paddle over disk, operating at 50 rpm in PBS with pH 7.2 equilibrated to 32 ± 0.5 °C.
Due to adequate solubility of fentanyl corresponding to its concentration and provision
of sink condition, 500 mL of PBS was used as dissolution medium. One patch was ap-
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Table IV. Composition of some typical polymeric mixtures used for the preparation of fentanyl DIAPs
Compound DIA 3 DIA Sus 5 DIA Sol 8 DIA 11 DIA 12
Fentanyl 5 5 5 5 5
Acronal® 25 37.5 50 – –
Eudragit® E 100 – – – 10 25
DBS – – – 4.5 11.2
Propylene glycol 5 7.5 10 – –
Succinic acid – – – 0.9 3.46
Organic solvents q. s. q. s. q. s. q. s. q. s.
DIA, Sus, and Sol denote drug-in-adhesive, suspension, and solution, respectively.
q. s. – quantum satis
Amounts are expressed in mg, except for alcohol and purified water which are in mL.
plied flat on the disk with the release surface facing up (effective area available to diffu-
sion was 10 cm2) and a support membrane on top of it. This membrane was rehydrated
by immersion in purified water 1 h before application. At predetermined time intervals,
5-mL samples were collected and immediately replenished with fresh medium. The sam-
ples were analyzed for their fentanyl content using the aforementioned HPLC method.
Adhesion properties
Peel adhesion 180° test. – One week after the preparation of TDDSs, they were cut in-
to strips, 2.5 cm wide and 15 cm long, and conditioned for 24 h at 23 ± 2 °C and 50 ± 5%
RH. The tests were performed with a tensile testing machine (Enrico Toniolo, Italy). The
strips were applied to an adherent plate made of stainless steel, smoothed with a stand-
ard roller (2.04 kg) five times and pulled from the plate at a 180° angle at a rate of 300
mm min–1 (15). The matrix had to peel cleanly from the plate, leaving no visually notice-
able residue in order to show neat removal. The forces were expressed in cN per cm
width of adhesive tape.
Thumb tack test. – One week after the preparation of TDDSs, the thumb was pressed
lightly on a patch for about 5 seconds and then quickly withdrawn (16). By varying the
pressure and time of contact, and considering the difficulty of pulling the thumb from
the adhesive, it was possible to set a scoring as to how easily, quickly, and strongly the
adhesive can form a bond with the skin. All the tests were simultaneously performed in
a blind way on three samples.
Creep resistance test. – One week after the preparation of TDDSs, they were cut preci-
sely into strips 2.5 cm wide and 6 cm long. 1.27 cm of the specimen was applied at the
tab end in contact with an adherent plate made of stainless steel. The specimen was laid
without pressure exactly parallel to the length of the test surface and smoothed using
the aforementioned method. The prepared sample was placed in the shear adhesion rack
to hold panels 2° inclined from the vertical so that the back of the panel formed an angle
of 178° with the extended piece of sample. A 500 g weight was secured to the free end of
the patch. The test was performed with an apparatus made in our laboratory according
to PSTC-1 specification (15, 16).
Simplified peel adhesion 180° test. – This simplified adhesion peel 180° test is a combi-
nation of the creep resistance and peel 180° tests and was developed in our laboratory.
The apparatus is similar to the creep resistance device but without any incline to the ver-
tical axis. The major disadvantage of the creep resistance test is that it is time consuming,
for example, for many moderate adhesives it may take long, even more than 2–4 hours.
On the other hand, the major disadvantage of the peel adhesion 180° test is the need to
use a tensile strength machine. These two problems have been solved in our simplified
test. In practice, adhesive patches were cut into strips, 2.5 cm wide and 15 cm long, con-
ditioned for 24 h at 23 ± 2 °C and 50 ± 5% RH. The samples, 6 cm of adhesive, were ap-
plied to an adherent plate made of stainless steel, smoothed using the aforementioned
method and peeled from the plate at a 180° angle by a 500 g mass. In this test, the peel-
ing time is reported in minutes.
307
Amir Mehdizadeh et al.: Design and in vitro evaluation of new drug-in-adhesive formulations of fentanyl transdermal patches, Acta
Pharm. 54 (2004) 301–317.
Data analysis
The cumulative amount permeated through the membrane per unit area was calcu-
lated from the concentration of each patch in the dissolution vessel and plotted as a fun-
ction of the square root of time (17).
Full factorial design of experiments was applied to investigate the effects of one ex-
perimental variable while keeping all the others constant (18).
Student’s t-test was performed to find any significant difference in the release rate
between our TDDSs and the reference commercially available product.
RESULTS AND DISCUSSION
Macroscopic and microscopic examination
No evidence of crystal growth due to solvent loos was observed in the solution for-
mulation. No pins or defective sealings were observed in RPs while they were evaluated
by the leaking test. Using a lab coater with minimum spreading length of 30 cm and 1 m
min–1 spreading speed, an average thickness of 130  11 µm (mean  SD) was obtained
form 5 experiments. This method decreased the relative standard deviation of thickness
to less than 8.5%. Several important parameters influence constant thickness. These in-
clude the minimum length and speed of film spreading, volume of polymer solution in
the device reservoir, and the polymer solution viscosity. Low viscosity leads to »bleed-
ing« of polymer solution beneath the film coater and high viscosity causes imperfect
film layers.
In vitro release of fentanyl
Developing a discriminating dissolution medium using a proper dissolution appa-
ratus is of tremendous value for a drug release study in TDDSs. The volume, pH, surfa-
ce tension, and viscosity of medium are the most important parameters to be considered
(9). Our analytical results showed that the solubility of fentanyl in water and PBS of pH
7.2 is 53 and 335 mg L–1, respectively. Therefore, both may provide the sink condition for
fentanyl patches without any surface active agents. In these experiments, 500 mL PBS
was selected as the discriminative dissolution medium since it created the sink condi-
tion.
Drug absorption into the skin generally, occurs by passive diffusion (19). The rate of









where dM/Sdt (J) is the steady-state flux across the stratum corneum, D is the diffusion
coefficient or diffusivity of drug molecules, c is the drug concentration gradient across
SC layer, K is the partition coefficient of the drug between skin and formulation me-
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dium, and h is the SC thickness (19). In other words, the rate of drug transport depends
not only on its aqueous solubility, but is also directly proportional to its oil/water parti-
tion coefficient, its concentration in the formulation vehicle, and the surface area of the
skin to which it is exposed; it is inversely proportional to the SC thickness.
Plot of the cumulative amount of drug released per unit area (g cm–2) against the
the square root of time according to the Higuchi equation yields a straight line; the slop-
pe of the regression line represents the release rate (8). This formula is an integral form
of the Higuchi equation (19):
Q = (2ADCs t)1/2 (2)
where Q is the cumulative amount of drug released per unit area of the matrix, A is the
total drug concentration in the matrix, dissolved and undissolved, D is the diffusion co-
efficient of the drug in the matrix, cs is the solubility or saturation concentration of the
drug in the matrix, and t is time (19–21). There is another form of the Higuchi equation,









where k is the release constant. Plot of dQ/dt against the reciprocal of the square root of
time leads to a straight line.
Drug release from RPs. – Drug release data for 10 cm2 and 20 cm2 reference fentanyl
RPs are summarized in Table V. Plotting the percent release of fentanyl from reference
formulation versus time gives the pattern of release (Fig. 1). As it is shown in Fig. 1, the
R2 value for 10 cm2 reference RP is 0.08, showing that the release kinetics is not of zero
order. Even considering the logical burst effect, and assuming 10 percent intercept, the
R2 value increased up to 0.5776, which indicates the non-linearity of the release profile.
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Fig. 1. Release of fentanyl from 10 cm2 (25 g h–1) refe-
rence formulation RPs (). Regression line without
considering the burst effect (----, no intercept, R2 =
0.08); regression line with considering the burst effect
—–, 10% intercept, R2 = 0.5776). Each value represen-
ts a mean of three tests with the corresponding SD.
Also dQ/dt in Table V indicates that the rate of fentanyl release decreases with time for
both 10 and 20 cm2 reference RPs. Moreover, Q values increase accordingly with the
square root of time and depict a linear correlation indicating that fentanyl release kine-
tics from reference RPs obey the Higuchi model.
Two fixing methods, with and without the support membrane, were performed ini-
tially in the release studies for reference patches in order to show the effect of the sup-
port membrane on TDDS fentanyl release. Results showed that the support membrane
had no significant influence on the release. Therefore, it was decided to perform all the
release experiments with Spectra/Por® 7 with cut off 14000 Daltons as the support mem-
brane to fix TDDS in the paddle over the disk apparatus.
Two main techniques are used to adjust fentanyl release in RPs: the first, which is
more common and easier, changes the type and caliper or thickness of the control mem-
brane, and the second changes the gel consistency, solution or suspension of the active
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Table V. Drug release data for reference fentanyl RPs
Time
(h)
10 cm2 (25 g h–1) RPs
dQ/dt




























Fig. 2. Effect of different control membranes on the drug
release of fentanyl RPs with the same gel formulation:  –
CotranTM control membrane 9728 (R2 = 0.8903),  – Cot-
ranTM control membrane 9702 (R2 = 0.9812),  – CotranTM
control membrane 9706 (R2 = 0.9775), and × – reference RPs
(R2 = 0.9816). Each value represents a mean of four tests
with the corresponding SD.
substance, and sometimes both factors might be changed in the formulation (5). In Fig.
2, release of fentanyl in solution formulation was adjusted by applying different control
membranes: Cotran® 9728, Cotran® 9702 and Cotran® 9706. It is shown that the amount
of VA in the control membrane is critical for the drug release due to fentanyl hydropho-
bicity. The amount of Q reached its maximum value within 24 h using Cotran® 9728,
while the amount of Q reached 60% within 72 h using Cotran® 9706. Due to high perme-
ability and lipophilicity of fentanyl and according to the obtained results, 9% VA with 50
and 100 m thick was used follows that both Cotran® 9728 and Cotran® 9706 are not ap-
propriate control membranes since they cause either a fast release of fentanyl (Cotran®
9728) or its insufficient release (Cotran® 9706) within 72 h. However, Cotran® 9702 resul-
ted in a desirable and complete release profile comparable to reference RPs within 72 h.
Thus, it can be used as a reliable control membrane in RP formulations.
As it is shown in Fig. 2, the R2 values are 0.9775, 0.9816, 0.9812 and 0.8903 for Cot-
ranTM 9706, reference product (RP), CotranTM 9702 and CotranTM 9728, respectively. So,
it shows that the reference product and three other formulations obey the Higuchi model.
The effects of changing the physical condition of formulations (solution and sus-
pension) are shown in Fig. 3. When fentanyl was formulated in the solution form plus
2% gel the release from RPs was faster compared to reference formulation, whereas fen-
tanyl in the suspension form plus 4% gel resulted in a slower release profile compared to
reference formulation. Therefore, a 3% HEC fentanyl solution and a 2% HEC fentanyl
suspension were made in order to adjust the release profile to the reference formulation.
As shown in Fig. 3, both of these recent formulations resulted in a release profile compa-
rable with reference formulation. Thus, the rate of drug release was dependent on both
the solution and suspension forms of fentanyl formulation and its gel consistency.
As Fig. 3 shows, all the formulations obey the Higuchi (square root of time) model.
The R2 values are 0.9775, 0.9632, 0.9816, 0.9810 and 0.9342 for suspension and 4% gel,
suspension and 2% gel reference RPs, solution and 3% gel, and solution and 2% gel, res-
pectively.
Drug release from MPs. – Different matrices were formulated by varying the concen-
trations of HPMC K4M, K15M and K100M, EC, HEC and Eudragit® E, whereas the drug
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Fig. 3. Effect of solution and suspension for-
mulations on the fentanyl drug release with
the same control membrane:  – R Sol 2 (R2 =
0.9342), – R Sol 8 (R2 = 0.9810), – referen-
ce RPs (R2 = 0.9816), × – R Sus 1 (R2 = 0.9632),
and  – R Sus 10 (R2 = 0.9775). Each value re-
presents a mean of three tests with the corres-
ponding SD.
concentration was kept constant at 5 mg fentanyl per 10 cm2. The important point is that
in contrast to RPs where 2.5 mg fentanyl was required for 10 cm2 to provide enough mo-
tor drive for drug diffusion, the MPs required twice as high a concentration per unit
area, namely 5 mg fentanyl per 10 cm2, in order to achieve the same motor drive.
As observed in Fig. 4, EC could not release fentanyl probably due to its hydropho-
bic properties. When dibutyl sebacate (DBS), was added to the formulation as a hydrop-
hobic plasticizer, release of fentanyl reached the maximum ob 10% of the reference for-
mulation after 72 h. Even replacing the plasticizer with a hydrophilic one, propylene
glycol, the release of fentanyl increased to at most 30% of reference formulation, which
is not enough. Therefore, although EC is a very good film forming polymer, it is not ap-
propriate for fentanyl.
HPMC K15M and K100M were not suitable matrices due to their high viscosity. Ap-
plication and spreading of these polymers with a lab coater was not possible and resul-
ted in non-homogenous matrix layers. It was possible to make a homogenous film from
HPMC K4M; however, the matrix thickness increased up to 600 m, which is not accept-
able with respect to patient compliance. Moreover, the release rate of fentanyl MPs for-
mulated with HPMC K4M was rapid, which is not appropriate for a 3-day TDDS formu-
lation (see Fig. 4).
As regards Eudragit® E, it was found that the amount of dry substance per square
meter should be 50–70 g corresponding to a layer thickness of 50–70 m. These thin lay-
ers, ready for application, are colorless, transparent and highly flexible. After preparing
and transferring the PSA sheet, they should be immediately protected with a release li-
ner, e.g., the 3M Scotch 1022 liner. It was also shown that DBS is not a suitable plasticizer
due to the hydrophobic nature of fentanyl. However, using PG as a hydrophilic plastici-
zer combined with Eudragit® E resulted in a release profile of fentanyl from MPs com-
parable to its release pattern from reference RPs (see Fig. 4). Therefore, a mixture of Eud-
ragit® E and PG can be an appropriate candidate matrix layer for the release of fentanyl
from MPs. The R2 values for all matrix formulations are close to that for the reference
formulation showing that MPs obey the Higuchi model.
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Fig. 4. Comparative release of fentanyl from dif-
ferent MPs and reference RPs:  – M Sus 5 (R2 =
0.9258),  – reference RPs (R2 = 0.9816),  – M 9
(R2 = 0.9527),  – M 15 (R2 = 0.9709), and × – M
Sol 8 (R2 = 0.8984). Each value represents mean
of four tests with the corresponding SD.
Drug release from DIAPs. – The most important part of this research was based on
formulating DIAPs, very thin and delicate patches. DIAPs are generally made of an or-
ganic adhesive mixture. Recently developed aqueous polymeric systems feature a num-
ber of advantages. Compared to organic solvents, water is more beneficial than any ot-
her agent because skin irritation and environment contamination are reduced. DIAPs
were fabricated using two methods: a) crosslinking of Eudragit® E with succinic acid
and a suitable plasticizer, b) using a liquid PSA such as Acronal® V 210.
As shown in Fig. 5 and Table VI, crosslinking of Eudragit® E did not yield adequate
adhesion properties. It is generally assumed that the carboxyl groups of the cohesion
promoter (e.g. succinic acid) enter into ionic interactions with the tertiary amino function
of Eudragit® E. Two neighboring polymer chains can thus be linked with each other,
which results in a modification of the system properties where the viscosity increases
with the proportion of succinic acid without giving rise to the formation of a crosslinked
solid body. The basic property of fentanyl may be the reason for inappropriate adhesion
and inadequate crosslinking of Eudragit® E (22–24). However, Acronal® V 210 (as shown
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Fig. 5. Comparison of peeling strengths of
different PSAs. Each value represents a mean
of three tests with the corresponding SD.








MA-31 +++ 108 234
HY-3 ++ 13 10
MA-46 +++ 174 375
3M-1524 +++ 192 372
Acronal +++ 187 325
Eudragit E 100 and 9% succinic acid – Negligible No adhering
Eudragit E 100 and 6% succinic acid + 12 19
+++ aggressive, immediately after applying patch, ++ moderate, immediately after applying patch,
+ weak, after exerting considerable pressure, – no adhesion.
in Fig. 5 and Table VI) provided a reliable self-adhesive polymer to control the release of
fentanyl from DIAPs. It should be mentioned that some rheological problems such as
»bleeding beneath the lab coater« were observed, which required some viscosity increas-
ing agents. Therefore, a mixture of 25 mg Acronal® and 12.5 mg HPMC K15 per patch
can be an appropriate candidate DIAP for the release of fentanyl (Fig. 6). Respective R2
values for DIA3, DIA Sol 8 reference RPs and DIA Sus 5 are 0.9676, 0.9812, 0.9816 and
0.9775. These data suggest that also these transdermal formulations obey the Higuchi
model.
Adhesion properties
Adhesion plays a vital role for the effectiveness of transdermal patches. The adhesi-
ve properties of TDDSs are fundamental and the entire delivery surface of the patch has
to maintain complete skin contact for the required period, 1 to 7 days or maybe even
more, to ensure an efficient drug delivery. The adhesive polymers used in TDDSs are
classified as PSAs and are defined as adhesives capable of bonding to surfaces with the
application of light pressure (16). The adhesive properties can be evaluated in terms of
»tack« and »peel«. Tack could be defined as the property that enables an adhesive to
form a bond with the surface of another material upon brief contact under light pressure
(11). Peel adhesion is the force required to peel away a strip of tape from a rigid surface
(23). It is necessary to quantify the adhesive properties of the PSA used as the adhesive
layer in these systems. Nowadays, there are several methods to determine the adhesive
strength of PSAs, including the peel adhesion 180° test, thumb tack test, and creep resis-
tance test (23, 24). A simple but precise method was developed in our laboratory by
combining the peel adhesion 180° test and creep resistance test. The former needs a ten-
sile strength apparatus that is not precisely controllable and the latter is a time-consuming
method. In our method (modified or simplified peel 180° test), the peeling time needed
to separate the patch from the plate is measured in minutes.
The obtained results of the peel adhesion 180° test revealed clear differences be-
tween the adhesions of various PSAs. MA-31 medical grade adhesive, a thermoplastic,
moderately aggressive, acrylic copolymer PSA and 3M-1524 transferring film, a mild ag-
gressive 62.5 m acrylic copolymer PSA, showed better adhesion than the others. This is
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Fig. 6. Release of fentanyl from 10 cm2 DIAP formulation and
reference RPs:  – DIA 3 (R2 = 0.9676),  – DIA Sol 8 (R2 =
0.9812), × – reference RPs (R2 = 0.9816), and  – DIA Sus 5
(R2 = 0.9775). Each value represents a mean of four tests with
the corresponding SD.
due to their polymeric side chains structure. An alternative to high cross-link density is
the use of grafted polymeric side chains, either alone or in combination with relatively
low cross-link density. With this approach, reinforcement is achieved primarily through
phase separation of the side chain within the continuous polymer network. The thick-
ness of PSA in 3M-1524 transferring PSA is another reason for its better adhesion. The
peeling strengths of different PSAs are shown in Fig. 5.
The tack properties and creep resistance results of different PSAs as well as the corres-
ponding peeling time are reported in Table VI. The obtained results showed that MA-31,
MA-46, 3M-1524 and Acronal® have the best adhesive properties to be used as PSAs in
patch formulations.
The adhesion properties in DIAPs are more important than in the two other TDDSs,
RPs and MPs, due to their incorporating a drug or some other polymeric substances in
the adhesive layer. This may cause some problems in their adhesion properties. Polymer
layers containing aminomethacrylate, Eudragit® E 100, sebacates and succinic acid per-
mit DIAPs to compensate the effects of drugs and excipients on the adhesive properties.
CONCLUSIONS
The choice of an appropriate control membrane and gelling polymer in RP formula-
tions are critical issues. The obtained data clearly demonstrate that the formulation of
fentanyl RPs (according to the drug release pattern of the reference formulation of fenta-
nyl RPs) was feasible with the drug in solution and in suspension using a Cotran® 9702
control membrane. The most important target in this research work was to develop new
drug-in-adhesive and matrix formulations for fentanyl TDDS. It was clearly shown that
acrylic PSAs, e.g. Acronal®, were able to control drug release as well as adhesive proper-
ties in DIAPs. It was also concluded that 50–70 g acrylic PSA per square meter created a
film layer 50–70 m thick, which can regulate the release of fentanyl from the matrix.
The present studies have confirmed that DIAPs and MPs of fentanyl are able to compete
with RPs due to the fact that the manufacturing processes for these transdermal patches
are easier, faster, and cheaper. It was demonstrated that propylene glycol as plasticizer
and release enhancer yields better film quality, flexibility, and conformability. Further-
more, a simple and rapid method (simplified peel 180° test) was developed for compar-
ing and evaluating the adhesion properties of PSAs in TDDSs.
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S A @ E T A K
Dizajniranje i in vitro evaluacija transdermalnih flastera fentanila
AMIR MEHDIZADEH, TAYEBE TOLIATE, MOHAMMAD REZA ROUINI, SHARYAR ABASHZADEH i FARID DORKOOSH
U radu su evaluirani razli~iti matriksni, adhezivni i spremi{ni ljekoviti oblici za trans-
dermalnu primjenu fentanila. U dizajniranju adhezivnih flastera (DIAPs) upotrebljene
su razli~ite vrste i koli~ine teku}ih adheziva osjetljivih na tlak (PSAs). Evaluirano je oslo-
ba|anje ljekovite tvari i adhezivna svojstva. Za mjerenje i usporedbu adhezivnih svojsta-
va transdermalnih flastera razvijena je vrlo jednostavna, ali precizna »metoda lju{tenja«.
Rezultati su pokazali da kinetika osloba|anja slijedi kvadratni korijen vremena (Higu-
chijev model), ukazuju}i na to da se ljekovita tvar osloba|a difuzijom. Pokazalo se da je
za svakih 10 cm2 DIAP-a za trodnevnu uporabu potrebno 3,3 mg fentanila. Ta koli~ina je
za spremi{ne i matriksne flastere iznosila 2,5, odnosno 5 mg. Najbolja adhezivna svoj-
stva i osloba|anje fentanila bilo je iz akrilatnih pripravaka.
Klju~ne rije~i: fentanil, transdermalni sustavi za isporuku lijekova, flasteri, osloba|anje ljekovite tvari
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